Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
INS068 Injection vs insulin glargine in type 2 diabetes mellitus inadequately controlled on oral antidiabetic drugs
CTR20230178Phase 3Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2023
- Modality
- Insulin and Analogs → Hormones & Growth Factors → Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of insulin sudelidec in type 2 diabetes mellitus (T2DM) (2 arms), sponsored by Hengrui Therapeutics. Primary endpoint: Change from baseline in HbA1c at week 26. Started Jan 2023; status: completed.
02
Drugs
insulin sudelidec
03
Conditions
type 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on CTR20230178.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20230178.